The effect of angiotensin-converting enzyme genotype on acute mountain sickness and summit success in trekkers attempting the summit of Mt. Kilimanjaro (5,895 m)

Eur J Appl Physiol. 2009 Feb;105(3):373-9. doi: 10.1007/s00421-008-0913-5. Epub 2008 Nov 22.

Abstract

The I-allele rather than the D-allele of the human angiotensin converting enzyme (ACE) gene has been associated with high-altitude mountaineering success. We investigated whether the I-allele was associated with summit success, and also with AMS development, in altitude-naïve trekkers. Subjects ascended from 1,860 m to the summit over 4 days (n = 34, 'direct-profile') or 5 days (n = 82, 'slower-profile'). Proportionally more II direct-profile subjects were successful than ID or DD, although the difference was not significant (100% of II subjects, 52% ID and 43% DD, P = 0.09). There was no difference in success amongst subjects on the slower-profile (50% II, 45% ID and 58% DD, P = 0.54). There was a non-significant trend for increasing AMS scores in ID/DD subjects. Amongst tourist trekkers on Mt. Kilimanjaro the I-allele is not associated with summit success. No evidence is found to support an association between ACE genotype and AMS development.

MeSH terms

  • Acclimatization / genetics
  • Acute Disease
  • Adult
  • Alleles
  • Altitude Sickness / enzymology*
  • Altitude Sickness / genetics*
  • Female
  • Gene Frequency*
  • Genetic Predisposition to Disease*
  • Humans
  • Male
  • Middle Aged
  • Mountaineering / physiology*
  • Peptidyl-Dipeptidase A / genetics*
  • Risk Factors
  • Tanzania
  • Time and Motion Studies

Substances

  • Peptidyl-Dipeptidase A